Key Drivers
- Margin Expansion
- Strong Cash Flow
- Heavy Leverage
AIAI Summary
DaVita still throws off solid cash flow, but the investment case has shifted from “stable compounder” to “cash-generative operator facing rising reimbursement and payer-mix pressure,” so the key takeaway is that earnings durability—not quarterly beats—is now the main risk to watch as leverage limits the margin of safety.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Expansion
- •Strong Cash Flow
- •Heavy Leverage
DVA showed solid profitability and strong cash generation, but its highly leveraged balance sheet, negative equity, and rising debt remain the main risks.
Price Behavior
Key Price Behavior Insights:
- •Failed Bounces
- •Support Test
- •Weak Momentum
DVA remains bearish after a sharp decline last month, with repeated bounce failures leaving $178–$180 as key support and $188–$189 as the first resistance to clear.
Sharp drop from the late-July peak with quick-failing rebounds in early
Sentiment & News
Key News Insights:
- •Earnings Beat
- •Margin Pressure
- •Guidance Reaffirmed
DaVita beat Q2 expectations and reaffirmed 2026 guidance on strong treatment volumes and free cash flow, but ongoing reimbursement and mix pressure, plus lower revenue per treatment, weighed on margins and the stock reaction.
The news is modestly positive operationally, but near-term upside may stay limited until reimbursement and payer-mix headwinds ease
Similar Companies in Healthcare
Other companies in the same sector with AI ratings